Overview

Study Evaluating AMG 424 in Subjects With Multiple Myeloma

Status:
Terminated
Trial end date:
2020-06-19
Target enrollment:
Participant gender:
Summary
A multi-center Phase 1, First-in-Human study conducted in 2 Parts, testing AMG 424 in subjects with relapsed/ refractory multiple myeloma.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen